Related Experiment Video
Updated: Jun 16, 2025
06:24
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
847
A Model of Butyrate Activity and Resistance in CRC
1Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania, USA.
Journal of Cellular and Molecular Medicine
|June 12, 2025
Summary
Dietary fiber
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Dietary fiber breakdown produces butyrate, a compound linked to reduced colorectal cancer (CRC) risk.
- Colorectal cancer can develop even with high-fiber diets, suggesting mechanisms of butyrate resistance.
- Understanding butyrate resistance is crucial for improving CRC chemoprevention.
Purpose of the Study:
- To model butyrate resistance in colorectal cancer cells in vitro.
- To identify mechanisms by which colorectal cancer cells evade butyrate's effects.
- To integrate findings into a model of butyrate-resistant colorectal cancer cell phenotypes.
Main Methods:
- Development of butyrate-resistant cell models.
- Analysis of signaling pathways involved in butyrate resistance.
- Literature review and integration of laboratory findings.
Main Results:
- Loss of p300 expression in resistant cells allows increased noncanonical Wnt signaling without differentiation.
- AKT/PKB survival signaling is activated in butyrate-resistant cells.
- Overexpression of Tcf3 suppresses butyrate-induced Wnt hyperactivation.
Conclusions:
- Butyrate resistance involves complex signaling pathway alterations, including Wnt and AKT/PKB pathways.
- Specific molecular changes like p300 loss and Tcf3 overexpression contribute to resistance.
- Elucidating butyrate resistance mechanisms can refine colorectal cancer prevention strategies.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
131
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
131
01:21Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153